Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 11 2023 - 7:30AM
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi platform
technology is designed to make immune cells more effective in
killing tumor cells, today announced the poster presentation of two
key preclinical studies of its INTASYL compound PH-894 at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics in Boston, Massachusetts on October 11th -15th.
The first study shows that melanoma cells treated with its
PH-894 compound makes them more recognizable to the immune cells.
Specifically, the treatment results in an increase in the tumor
marker MART-1 (Melanoma tumor-associated antigen) allowing for
better recognition and potentially increased killing by T cells.
Local treatment with PH-894 presents a strategy to decrease BRD4
expression and upregulate MART-1 expression to increase immune
response to cancer cells while reducing toxicities associated with
systemic therapies. This study supports further development of
PH-894 for injectable solid tumor indications such as melanoma.
The second study demonstrates the effectiveness of PH-894 as an
antitumor cytotoxic agent (directly killing tumor cells). The
addition of PH-894 to cells in vitro elicited
concentration-associated apoptosis of all human cancer cell lines
tested, including head and neck squamous cell carcinoma (HNSCC),
hepatocellular carcinoma (HCC), breast cancer, lung cancer,
glioblastoma, melanoma, colon cancer, ovarian cancer, and cervical
cancer.
INTASYL PH-894, a precision self-delivering RNAi therapy, is
administered locally and is designed to provide a novel, safer
strategy to realize the enormous therapeutic potential of BRD4
inhibition for cancer that has been difficult to attain for small
molecule modalities that rely on systemic approaches that generate
significant toxicity.
Presentation Details:
Poster
Title: |
INTASYL™
PH-894 self-delivering RNAi targeting BRD4 enhances the
antigenicity of melanoma cells through MART-1 upregulation |
|
|
Session Date and Time: |
Saturday, October 14 | 12:30 pm-4:00 pm |
|
|
Poster Title: |
INTASYL™ self-delivering RNAi therapeutic targeting BRD4
elicits on-target apoptosis of human tumor cells |
|
|
Session Date and Time: |
Saturday, October 14 | 12:30 pm-4:00 pm |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi technology is
designed to make immune cells more effective in killing tumor
cells. INTASYL is the only self-delivering RNAi technology focused
on immuno-oncology therapeutics. INTASYL drugs precisely target
specific proteins that reduce the body's ability to fight cancer,
without the need for specialized formulations or drug delivery
systems.
For additional information, visit the Company's website,
www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Examples of forward looking statements
include statements regarding PH-894’s potential to increase tumor
marker MART-1 and potentially increase killing by T cells, the
effectiveness of PH-894 as an antitumor cytotoxic agent and the
potential of PH-894 to provide a safer strategy as a cancer
therapeutic. Our actual results may differ materially from those
indicated in the forward-looking statements as a result of a number
of important factors, including, but not limited to, the impact to
our business and operations by the inflationary pressures, rising
interest rates, recession fears, the development of our product
candidates, results from our preclinical and clinical activities,
our ability to execute on business strategies, our ability to
develop our product candidates with collaboration partners, and the
success of any such collaborations, the timeline and duration for
advancing our product candidates into clinical development, the
timing or likelihood of regulatory filings and approvals, the
success of our efforts to commercialize our product candidates if
approved, our ability to manufacture and supply our product
candidates for clinical activities, and for commercial use if
approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact: Phio Pharmaceuticals
Corp. ir@phiopharma.com
PR Contact Michael Adams Bridge View
Media adams@bridgeviewmedia.com
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2023 to Aug 2024